Bridging innate and adaptive tumor immunity: cGAS-STING pathway activation to potentiate immune checkpoint blockade

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway is a crucial component of innate immunity, detecting cytoplasmic DNA and initiating type I interferon signaling.
• Pharmacological activation of the cGAS-STING pathway is a promising strategy for cancer immunotherapy, particularly in combination with immune checkpoint inhibitors (ICIs).

Purpose of the Study:

• This review provides an overview of the current status of cGAS-STING agonists in cancer therapy.
• It emphasizes preclinical and clinical advancements in combination therapy with ICIs.
• The review also discusses challenges and future directions for optimizing efficacy and safety.

Main Methods:

• Review of preclinical studies demonstrating synergistic antitumor effects of cGAS-STING agonists and ICIs.
• Analysis of early-phase clinical trials assessing the safety and efficacy of this combination therapy.
• Discussion of intrinsic tumor resistance, immunosuppressive tumor microenvironment (TME), and immune toxicities as obstacles.

Main Results:

• Preclinical data show synergistic antitumor effects of cGAS-STING agonists and ICIs in various tumor models.
• Early clinical trials are investigating the safety and efficacy of these combinations in patients.
• Significant challenges remain, including intrinsic tumor resistance, an immunosuppressive TME, and therapy-associated immune toxicities.

Conclusions:

• The combination of cGAS-STING agonists and ICIs holds significant therapeutic potential in oncology.
• Addressing challenges like tumor resistance and immune toxicities is essential for clinical success.
• Further research and strategic optimization are needed to fully realize the benefits of cGAS-STING pathway activation in cancer treatment.